Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

Launched by HÔPITAL LE VINATIER · Jun 23, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of marker called neurofilament light chains to help doctors better understand and differentiate between cognitive and behavioral disorders caused by psychiatric issues, like schizophrenia and bipolar disorder, versus those caused by neurodegenerative diseases, such as Alzheimer’s disease and frontotemporal dementia (FTD). The researchers believe that measuring these markers in the blood can improve how these conditions are diagnosed and managed, ultimately leading to better care for patients.

To participate in this trial, individuals aged between 45 and 80 years old who have been diagnosed with schizophrenia or bipolar disorder (with or without cognitive decline) or those with probable or definite FTD or Alzheimer’s disease may be eligible. Participants will be asked to provide written consent and will undergo tests to measure their neurofilament levels, as well as other related markers in their blood. If you or someone you know is interested in joining this study, it’s important to discuss it with a healthcare provider to understand if it’s a good fit based on the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • haven given written consent
• Participants with psychiatric conditions:
• • Schizophrenia (DSM-V criteria) with or without cognitive involution
• • Bipolar disorder (DSM-V criteria) with or without cognitive involution
• Participants with neurodegenerative disease:
• • probable or definite FTD (Rascovsky criteria 2011)
• • Biological Alzheimer's disease with typical CSF (NIA-AA 2011)
• Exclusion Criteria:
• • Uninterviewable patient and/or missing history
• • History of recent or previous head trauma with loss of consciousness
• • History of ischemic or hemorrhagic stroke
• • Chronic alcoholism / chronic drug use
• • Progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy
• • Age \< 45 years
• • Age \> 80 years
• • Electroconvulsive therapy for less than 6 months